Medical oncology consultant
0161 918 7672
0161 446 8342
MB, BChir, PhD, MRCP
Experimental Cancer Medicine (Phase I trials) and Immunotherapy
Started at The Christie (Year)
Prof. Fiona Thistlethwaite is a Medical Oncology Consultant within the Experimental Cancer Medicines Team (ECMT), Cell Therapy Team leader and Director of iMATCH (Innovate Manchester Advanced Therapy Centre Hub).
Prof. Thistlethwaite is an Honorary Senior Lecturer at The University of Manchester. She graduated from The University of Cambridge MB PhD programme in 1999. Her PhD, under the supervision of Professor Sir Martin Evans, explored the molecular mechanisms that lead to cancer in inherited breast cancer syndromes.
Following training posts at Liverpool Royal, The Royal Marsden and The Christie, she became a consultant at The Christie in 2007. Her clinical practice is in Experimental Cancer Medicine and immune-oncology and her academic focus is clinical trial development in immunotherapy and adoptive T-cell therapy.
Prof. Thistlethwaite is a member of the ESMO Congress Scientific Committee (Immunotherapy Track) and has been an invited speaker at ESMO Congress and also hosted an immuno-oncology preceptorship meeting at The Christie School of Oncology. Fiona leads a recently formed Manchester health consortium, iMATCH, which has been awarded almost £7 million by Innovate UK to ensure that more patients benefit from a new generation of advanced cell therapies
Prof. Thistlethwaite has an active clinical trials research portfolio in early phase clinical trials (adult solid tumours) within the ECMT. Fiona has a particular focus on immune-oncology, in particular adoptive cell therapies, combination immunotherapies and immune biomarkers. Among Fiona’s research interests is how the immune system can be harnessed against cancer, in particular using adoptive cell transfer of T-cells activated against cancer antigens.
Prof. Thistlethwaite is an educational and clinical supervisor of doctors in training and lectures at The University of Manchester, including the MRes in Experimental Cancer Medicine.